A recent analysis of National Cancer Database showed that men with HER2-positive breast cancer have 60% lower odds of achieving pathologic complete response to neoadjuvant chemotherapy compared with women of the same subtype [23, 24]. Here, ERBB2 is linked to breast carcinoma.